• 1
    Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA: Cancer J Clin. 2012;62:220-241.
  • 2
    Ganz PA. Survivorship: adult cancer survivors. Prim Care. 2009;36:721-741.
  • 3
    Hewitt M, Greenfield S, Stoval E, et al. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2006.
  • 4
    Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers. CA Cancer J Clin. 2013;63:147-150.
  • 5
    Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112:543-547.
  • 6
    Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
  • 7
    Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
  • 8
    Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-5963.
  • 9
    Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383.
  • 10
    Chamie K, Connor SE, Maliski SL, Fink A, Kwan L, Litwin MS. Prostate cancer survivorship: lessons from caring for the uninsured. Urol Oncol. 2012;30:102-108.
  • 11
    Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2011;117:2779-2790.
  • 12
    Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol. 2007;177:1992-1999.
  • 13
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117-1123.
  • 14
    Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009;181:1622-1627; discussion 1627.
  • 15
    The Dartmouth Atlas of Health Care. 2938. Accessed April 7, 2014.
  • 16
    Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006;106:789-795.
  • 17
    Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010;184:1931-1936.
  • 18
    Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195-200.
  • 19
    Penner LA, Eggly S, Griggs JJ, Underwood W 3rd, Orom H, Albrecht TL. Life-threatening disparities: the treatment of black and white cancer patients. J Soc Issues. 2012;68(2).
  • 20
    Underwood W 3rd, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer. 2005;103:538-545.
  • 21
    Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290-1314.
  • 22
    American Cancer Society. Prostate cancer: expectant management (watchful waiting) and active surveillance for prostate cancer. Accessed April 4, 2014.
  • 23
    Dall”Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650-1659.
  • 24
    Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance among men undergoing expectant management for early-stage prostate cancer [published online ahead of print February 8, 2014]. J Urol. pii: S0022-5347(14)00230-4. doi:10.1016/j.juro. 2014.01.105.
  • 25
    Harrop JP, Dean JA, Paskett ED. Cancer survivorship research: a review of the literature and summary of current NCI-designated cancer center projects. Cancer Epidemiol Biomarkers Prev. 2011;20:2042-2047.
  • 26
    Darwish-Yassine M, Berenji M, Wing D, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Surviv. 2014;8:121-130.
  • 27
    Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101:888-892.
  • 28
    Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196-213.
  • 29
    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
  • 30
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
  • 31
    Grunfeld EA, Drudge-Coates L, Rixon L, Eaton E, Cooper AF. “The only way I know how to live is to work”: a qualitative study of work following treatment for prostate cancer. Health Psychol. 2013;32:75-82.
  • 32
    Reeve BB, Chen RC, Moore DT, et al. Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies [published online ahead of print March 3, 2014]. BJU Int. doi: 10.1111/bju.12723.
  • 33
    Hu JC, Kwan L, Krupski TL, et al. Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology. 2008;72:1274-1279.
  • 34
    Schroeck FR, Krupski TL, Sun L, et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008;54:785-793.
  • 35
    Collingwood SA, McBride RB, Leapman M, et al. Decisional regret after robotic-assisted laparoscopic prostatectomy is higher in African American men [published online ahead of print January 9, 2014]. Urol Oncol.
  • 36
    Johnson TK, Gilliland FD, Hoffman RM, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol. 2004;22:4193-4201.
  • 37
    Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol. 2005;23:7881-7888.
  • 38
    Singh J, Trabulsi EJ, Gomella LG. The quality-of-life impact of prostate cancer treatments. Curr Urol Rep. 2010;11:139-146.
  • 39
    Kleinmann N, Zaorsky NG, Showalter TN, Gomella LG, Lallas CD, Trabulsi EJ. The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat Rev Urol. 2012;9:258-265.
  • 40
    National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology (NCCN Guideline®): prostate cancer, version 1.2014. Accessed April 1, 2013.
  • 41
    National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology (NCCN Guideline®): survivorship, version 1.2014. Accessed May 20, 2013.
  • 42
    Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol. 2009;27:2489-2495.
  • 43
    Chubak J, Aiello Bowles EJ, Tuzzio L, et al. Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system [published online ahead of print December 19, 2013]. J Cancer Surviv.
  • 44
    Chubak J, Tuzzio L, Hsu C, et al. Providing care for cancer survivors in integrated health care delivery systems: practices, challenges, and research opportunities. J Oncol Pract. 2012;8:184-189.
  • 45
    Klabunde CN, Han PK, Earle CC, et al. Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med. 2013;45:463-474.
  • 46
    Potosky AL, Han PK, Rowland J, et al. Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med. 2011;26:1403-1410.
  • 47
    Skolarus TA, Miller DC, Zhang Y, Hollingsworth JM, Hollenbeck BK. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol. 2010;184:2279-2284.
  • 48
    Lance Armstrong Foundation. A National Action Plan for Cancer Survivorship: Advancing Public Health Strategies. Austin, TX: Lance Armstrong Foundation; 2004. Accessed April 9, 2014.
  • 49
    National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology: distress management, version 2.2013. Accessed May 22, 2013.
  • 50
    Michigan Cancer Consortium Prostate Cancer Action Committee. Michigan Cancer Consortium recommendations for prostate cancer survivorship care. Accessed September 13, 2012.
  • 51
    The University of Texas MD Anderson Cancer Center. Survivorship-prostate cancer, version 3. Accessed April 7, 2014.
  • 52
    Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495-2499.
  • 53
    Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243-274.
  • 54
    Galbraith ME, Hays L, Tanner T. What men say about surviving prostate cancer: complexities represented in a decade of comments. Clin J Oncol Nurs. 2012;16:65-72.
  • 55
    McInnes DK, Cleary PD, Stein KD, Ding L, Mehta CC, Ayanian JZ. Perceptions of cancer-related information among cancer survivors: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2008;113:1471-1479.
  • 56
    Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7:253-261.
  • 57
    Chan JM, Van Blarigan EL, Kenfield SA. What should we tell prostate cancer patients about (secondary) prevention? Curr Opin Urol. 2014;24:318-323.
  • 58
    Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
  • 59
    Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4:486-501.
  • 60
    Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012;21:1244-1259.
  • 61
    Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446-453.
  • 62
    Hu MB, Xu H, Bai PD, Jiang HW, Ding Q. Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients. Med Oncol. 2014;31:829.
  • 63
    Demark-Wahnefried W, Morey MC, Sloane R, et al. Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors. J Clin Oncol. 2012;30:2354-2361.
  • 64
    Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726-732.
  • 65
    Santa Mina D, Guglietti CL, Alibhai SM, et al. The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer [published online ahead of print December 7, 2013]. J Cancer Surviv.
  • 66
    Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008;16:987-997.
  • 67
    Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23:5814-5830.
  • 68
    Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J Clin Oncol. 2010;28:4066-4073.
  • 69
    Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. Ann Oncol. 2013;24:2699-2704.
  • 70
    Moreira DM, Aronson WJ, Terris MK, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014;120:197-204.
  • 71
    Agency for Healthcare Research and Quality. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD; Agency for Healthcare Research and Quality; 2008. Accessed April 4, 2014.
  • 72
    Dinnes J, Hewison J, Altman DG, Deeks JJ. The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer. Can Med Assoc J. 2012;184:169-177.
  • 73
    Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11:14-23.
  • 74
    Skolarus TA, Holmes-Rovner M, Northouse LL, et al. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013;31:727-732.
  • 75
    Underwood W 3rd, Orom H, Poch M, et al. Multiple physician recommendations for prostate cancer treatment: a Pandora's box for patients? Can J Urol. 2010;17:5346-5354.
  • 76
    Morgan TM, Meng MV, Cooperberg MR, et al. A risk-adjusted definition of biochemical recurrence after radical prostatectomy [published online ahead of print 2014]. Prostate Cancer Prostatic Dis. doi: 10.1038/pcan. 2014.5.
  • 77
    Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973-3978.
  • 78
    Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
  • 79
    Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;69:426-433.
  • 80
    Mehta NH, Kamrava M, Wang PC, Steinberg M, Demanes J. Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;86:729-733.
  • 81
    Thompson A, Keyes M, Pickles T, et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys. 2010;78:415-421.
  • 82
    Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
  • 83
    Malik R, Jani AB, Liauw SL. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1022-1028.
  • 84
    Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J; PROBATE group of the GEC ESTRO. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol. 2014;110:213-228.
  • 85
    Musunuru H, Mason M, Murray L, et al. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer. Clin Oncol (R Coll Radiol). 2014;26:210-215.
  • 86
    Sountoulides P, Koletsas N, Kikidakis D, Paschalidis K, Sofikitis N. Secondary malignancies following radiotherapy for prostate cancer. Ther Adv Urol. 2010;2:119-125.
  • 87
    Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology. 2005;128:819-824.
  • 88
    Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg. 2011;254:947-950.
  • 89
    Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180:2005-2009; discussion 2009-2010.
  • 90
    Reeve BB, Stover AM, Jensen RE, et al. Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. Cancer. 2012;118:5679-5687.
  • 91
    Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17:307-319.
  • 92
    Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245-250.
  • 93
    Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.
  • 94
    Bayraktar Z, Atun AI. Despite some comprehension problems the International Index of Erectile Function is a reliable questionnaire in erectile dysfunction. Urol Int. 2012;88:170-176.
  • 95
    Chang P, Szymanski KM, Dunn RL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186:865-872.
  • 96
    Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245-1250.
  • 97
    Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011;40:655-671.
  • 98
    Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14:187-192.
  • 99
    Do NL, Nagle D, Poylin VY. Radiation proctitis: current strategies in management. Gastroenterol Res Pract 2011;2011:917941.
  • 100
    Richter JM, Kushkuley S, Barrett JA, Oster G. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. Aliment Pharmacol Ther. 2012;36:248-256.
  • 101
    Hampson NB, Holm JR, Wreford-Brown CE, Feldmeier J. Prospective assessment of outcomes in 411 patients treated with hyperbaric oxygen for chronic radiation tissue injury. Cancer. 2012;118:3860-3868.
  • 102
    Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf). 2011;74:289-293.
  • 103
    Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388-2399.
  • 104
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27:92-99.
  • 105
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54:816-823.
  • 106
    Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591.
  • 107
    Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189(suppl 1):S34-S42; discussion S43-S44.
  • 108
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
  • 109
    Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359-2366.
  • 110
    Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111:543-548.
  • 111
    Levine GN, D'Amico AV, Berger P, et al; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society; and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60:194-201.
  • 112
    Collins L, Basaria S. Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. Asian J Androl. 2012;14:222-225.
  • 113
    Weber BA, Sherwill-Navarro P. Psychosocial consequences of prostate cancer: 30 years of research. Geriat Nurs. 2005;26:166-175.
  • 114
    Zenger M, Lehmann-Laue A, Stolzenburg JU, Schwalenberg T, Ried A, Hinz A. The relationship of quality of life and distress in prostate cancer patients compared to the general population. Psychosoc Med. 2010;7:Doc02.
  • 115
    Carlson LE, Angen M, Cullum J, et al. High levels of untreated distress and fatigue in cancer patients. Br J Cancer. 2004;90:2297-2304.
  • 116
    Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ. The burden of depression in prostate cancer. Psychooncology. 2012;21:1338-1345.
  • 117
    Korfage IJ, Essink-Bot ML, Janssens AC, Schroder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer. 2006;94:1093-1098.
  • 118
    Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013;112:E67-E75.
  • 119
    Anguiano L, Mayer DK, Piven ML, Rosenstein D. A literature review of suicide in cancer patients. Cancer Nurs. 2012;35:E14-E26.
  • 120
    Misono S, Weiss NS, Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. J Clin Oncol. 2008;26:4731-4738.
  • 121
    Monahan PO, Champion V, Rawl S, et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? Qual Life Res. 2007;16:399-411.
  • 122
    Norris L; Pratt-Chapman M; Noblick JA, Cowens-Alvarado R. Distress, demoralization, and depression in cancer survivorship. Psychiatric Anals. 2011;41:433438.
  • 123
    Badger TA, Segrin C, Figueredo AJ, et al. Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Qual Life Res. 2011;20:833-844.
  • 124
    Traeger L, Cannon S, Keating NL, et al. Race by sex differences in depression symptoms and psychosocial service use among non-Hispanic black and white patients with lung cancer. J Clin Oncol. 2014;32:107-113.
  • 125
    Zhang AY, Gary F, Zhu H. What precipitates depression in African-American cancer patients? Triggers and stressors. Palliat Support Care. 2012;10:279-286.
  • 126
    Carlson LE, Groff SL, Maciejewski O, Bultz BD. Screening for distress in lung and breast cancer outpatients: a randomized controlled trial. J Clin Oncol. 2010;28:4884-4891.
  • 127
    Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. Psychooncology. 2014;23:195-203.
  • 128
    Mitchell AJ. Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis. J Natl Compr Canc Netw. 2010;8:487-494.
  • 129
    Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.
  • 130
    Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med. 2011;8:560-566.
  • 131
    Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104:990-1004.
  • 132
    Meijer A, Roseman M, Delisle VC, et al. Effects of screening for psychological distress on patient outcomes in cancer: a systematic review. J Psychosom Res. 2013;75:1-17.
  • 133
    Casey RG, Corcoran NM, Goldenberg SL. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl. 2012;14:226-231.
  • 134
    Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70:235-255.
  • 135
    Johansson E, Steineck G, Holmberg L, et al; SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12:891-899.
  • 136
    Kazer MW, Bailey DE Jr, Chipman J, et al. Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. BJU Int. 2013;111(3 pt B):E84-E91.
  • 137
    Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104:467-478.
  • 138
    Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 pt 1):826-831; discussion 831-822.
  • 139
    Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male. 2010;13:1-9.
  • 140
    Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007;177:17-24.
  • 141
    VanderWalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin. 2011;61:139-156.
  • 142
    Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol. 2008;5:24-34.
  • 143
    Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918-923.
  • 144
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
  • 145
    Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013;111:745-752.
  • 146
    Elliott SP, Jarosek SL, Alanee SR, Konety BR, Dusenbery KE, Virnig BA. Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer. 2011;117:4557-4565.
  • 147
    Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
  • 148
    Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175-1184.
  • 149
    Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Cancer Netw. 2009;7(suppl 3):S1-S32; quiz S33-S35.
  • 150
    Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010;183:2200-2205.
  • 151
    Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:20-27.
  • 152
    Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-1822.
  • 153
    Akbal C, Tinay I, Simsek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol. 2008;40:355-363.
  • 154
    Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306:1205-1214.
  • 155
    Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol. 2010;20:234-240.
  • 156
    Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008;18:613-620.
  • 157
    Stember DS, Mulhall JP. The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer. Brachytherapy. 2012;11:87-96.
  • 158
    Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. J Urol. 2009;182:649-654.
  • 159
    Brewer ME, Kim ED. Penile rehabilitation therapy with PDE-V inhibitors following radical prostatectomy: proceed with caution. Adv Urol. 2009:852437.
  • 160
    Hakky TS, Baumgarten AS, Parker J, et al. Penile rehabilitation: the evolutionary concept in the management of erectile dysfunction. Curr Urol Rep. 2014;15:393.
  • 161
    McCullough AR. Rehabilitation of erectile function following radical prostatectomy. Asian J Androl. 2008;10:61-74.
  • 162
    Aydogdu O, Gokce MI, Burgu B, Baltaci S, Yaman O. Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy. Int Braz J Urol. 2011;37:336-344; discussion 344-346.
  • 163
    Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int. 2013;111:658-665.
  • 164
    Briganti A, Di Trapani E, Abdollah F, et al. Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. J Sex Med. 2012;9:608-617.
  • 165
    Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med. 2009;6:1794-1808; quiz 1793, 1809-1810.
  • 166
    Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902-912.
  • 167
    Mitchell SA, Jain RK, Laze J, Lepor H. Post-prostatectomy incontinence during sexual activity: a single center prevalence study. J Urol. 2011;186:982-985.
  • 168
    Nilsson AE, Carlsson S, Johansson E, et al. Orgasm-associated urinary incontinence and sexual life after radical prostatectomy. J Sex Med. 2011;8:2632-2639.
  • 169
    Eylert MF, Bahl A, Persad R. Do we need to obtain consent for penile shortening as a complication of treatment for organ-confined prostate cancer? BJU Int. 2012;110:1491-1500.
  • 170
    Brison D, Seftel A, Sadeghi-Nejad H. The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med. 2013;10:1124-1135.
  • 171
    Pahlajani G, Raina R, Jones S, Ali M, Zippe C. Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med. 2012;9:1182-1189.
  • 172
    Yuan J, Hoang AN, Romero CA, Lin H, Dai Y, Wang R. Vacuum therapy in erectile dysfunction–science and clinical evidence. Int J Impot Res. 2010;22:211-219.
  • 173
    Porst H, Burnett A, Brock G, et al; ISSM Standards Committee for Sexual Medicine. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130-171.
  • 174
    Pardo Y, Guedea F, Aguilo F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28:4687-4696.
  • 175
    Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Curr Urol Rep. 2004;5:212-219.
  • 176
    Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009;24(suppl 2):S389-S394.
  • 177
    Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol. 2012;30:3720-3725.
  • 178
    Pastuszak AW, Badhiwala N, Lipshultz LI, Khera M. Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int J Impot Res. 2013;25:194-199.
  • 179
    De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis. 2012;15:120-127.
  • 180
    Wittmann D, Northouse L, Foley S, et al. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res. 2009;21:99-106.
  • 181
    Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013;22:756-761.
  • 182
    Wassersug RJ, Lyons A, Duncan D, Dowsett GW, Pitts M. Diagnostic and outcome differences between heterosexual and nonheterosexual men treated for prostate cancer. Urology. 2013;82:565-571.
  • 183
    van den Bergh RC, Korfage IJ, Roobol MJ, et al. Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Int. 2012;110:1032-1039.
  • 184
    Nelson CJ, Choi JM, Mulhall JP, Roth AJ. Determinants of sexual satisfaction in men with prostate cancer. J Sex Med. 2007;4:1422-1427.
  • 185
    Chambers SK, Schover L, Nielsen L, et al. Couple distress after localised prostate cancer. Support Care Cancer. 2013;21:2967-2976.
  • 186
    Eisemann N, Waldmann A, Rohde V, Katalinic A. Quality of life in partners of patients with localised prostate cancer [published online ahead of print December 8, 2013]. Qual Life Res.
  • 187
    Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology. 2006;68(suppl 3):26-37.
  • 188
    Tanner T, Galbraith M, Hays L. From a woman's perspective: life as a partner of a prostate cancer survivor. J Midwifery Womens Health. 2011;56:154-160.
  • 189
    Garos S, Kluck A, Aronoff D. Prostate cancer patients and their partners: differences in satisfaction indices and psychological variables. J Sex Med. 2007;4:1394-1403.
  • 190
    Segrin C, Badger TA, Harrington J. Interdependent psychological quality of life in dyads adjusting to prostate cancer. Health Psychol. 2012;31:70-79.
  • 191
    Abraham NE, Makarov DV, Laze J, Stefanovics E, Desai R, Lepor H. Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomy. J Urol. 2010;184:1977-1981.
  • 192
    Galbraith ME, Fink R, Wilkins GG. Couples surviving prostate cancer: challenges in their lives and relationships. Semin Oncol Nurs. 2011;27:300-308.
  • 193
    Schover LR, Canada AL, Yuan Y, et al. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer. 2012;118:500-509.
  • 194
    Wittmann D, Montie JE, Hamstra DA, Sandler H, Wood DP Jr. Counseling patients about sexual health when considering post-prostatectomy radiation treatment. Int J Impot Res. 2009;21:275-284.
  • 195
    Reese JB. Coping with sexual concerns after cancer. Curr Opin Oncol. 2011;23:313-321.
  • 196
    Reese JB, Keefe FJ, Somers TJ, Abernethy AP. Coping with sexual concerns after cancer: the use of flexible coping. Support Care Cancer. 2010;18:785-800.
  • 197
    Couper J, Bloch S, Love A, Macvean M, Duchesne GM, Kissane D. Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature. Psychooncology. 2006;15:937-953.
  • 198
    Heins M, Schellevis F, Rijken M, Donker G, van der Hoek L, Korevaar J. Partners of cancer patients consult their GPs significantly more often with both somatic and psychosocial problems. Scand J Prim Health Care. 2013;31:203-208.
  • 199
    Resendes LA, McCorkle R. Spousal responses to prostate cancer: an integrative review. Cancer Invest. 2006;24:192-198.
  • 200
    Ko CM, Malcarne VL, Varni JW, et al. Problem-solving and distress in prostate cancer patients and their spousal caregivers. Support Care Cancer. 2005;13:367-374.
  • 201
    Harden J. Developmental life stage and couples' experiences with prostate cancer: a review of the literature. Cancer Nurs. 2005;28:85-98.
  • 202
    Tyson MD, Andrews PE, Etzioni DA, et al. Marital status and prostate cancer outcomes. Can J Urol. 2013;20:6702-6706.
  • 203
    Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64:672-679.
  • 204
    Radomski SB. Practical evaluation of post-prostatectomy incontinence. Can Urol Assoc J. 2013;7(9–10 suppl 4):S186-S188.
  • 205
    Sandhu JS, Eastham JA. Factors predicting early return of continence after radical prostatectomy. Curr Urol Rep. 2010;11:191-197.
  • 206
    Skolarus TA, Weizer AZ, Hedgepeth RC, He C, Wood DP Jr, Hollenbeck BK. Understanding early functional recovery after robotic prostatectomy. Surg Innov. 2012;19:5-10.
  • 207
    Srivastava A, Peyser A, Gruschow S, Harneja N, Jiskrova K, Tewari AK. Surgical strategies to promote early continence recovery after robotic radical prostatectomy. Arch Esp Urol. 2012;65:529-541.
  • 208
    Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2012;1:CD001843.
  • 209
    Goode PS, Burgio KL, Johnson TM 2nd, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305:151-159.
  • 210
    Chung E, Cartmill R. Diagnostic challenges in the evaluation of persistent or recurrent urinary incontinence after artificial urinary sphincter (AUS) implantation in patients after prostatectomy. BJU Int. 2013;112(suppl 2):32-35.
  • 211
    Comiter CV. Male incontinence surgery in the 21st century: past, present, and future. Curr Opin Urol. 2010;20:302-308.
  • 212
    Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.
  • 213
    Herschorn S. Update on management of post-prostatectomy incontinence in 2013. Can Urol Assoc J. 2013;7(9–10 suppl 4):S189-S191.
  • 214
    Fisher WI, Johnson AK, Elkins GR, et al. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin. 2013;63:167-192.
  • 215
    Engstrom CA. Hot flashes in prostate cancer: state of the science. Am J Mens Health. 2008;2:122-132.
  • 216
    Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer. 2013;11:375-384.
  • 217
    Alekshun TJ, Patterson SG. Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy. Support Cancer Ther. 2006;4:30-37.
  • 218
    Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009;20:542-549.
  • 219
    American College of Surgeons Commission on Cancer. Cancer program standards 2012: ensuring patient-centered care, version 1.2.1. Accessed January 16, 2014.
  • 220
    Chipman JJ, Sanda MG, Dunn RL, et al; PROST-QA Consortium. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol. 2014;191:638-645.
  • 221
    Heins MJ, Korevaar JC, Rijken PM, Schellevis FG. For which health problems do cancer survivors visit their General Practitioner? Eur J Cancer. 2013;49:211-218.
  • 222
    Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32:833-840.